A patient with cannabinoid hyperemesis syndrome who did not respond to standard treatments found relief with haloperidol, suggesting a new treatment option for this difficult condition.
Read this if you or someone you know experiences severe vomiting episodes related to cannabis use.
Haloperidol resolved CHS symptoms when standard antiemetics failed
What the researchers found
This case report documented a patient with cannabinoid hyperemesis syndrome (CHS), a condition characterized by severe cyclic vomiting, nausea, and abdominal pain in people who use cannabis chronically.
CHS is often unrecognized or misdiagnosed, leading to unnecessary medical workups and repeated hospitalizations. While long-term abstinence from cannabis is the definitive treatment, managing acute episodes has been challenging for clinicians.
In this case, haloperidol (an antipsychotic medication) successfully resolved the patient's symptoms when other conventional treatments had failed. The authors highlight haloperidol as a safe and effective acute treatment option for the unrelenting symptoms of CHS.
Why it matters
CHS is increasingly recognized as cannabis use has expanded, and emergency physicians need effective acute treatments. This case adds to growing evidence that haloperidol may be particularly effective for CHS, potentially because it blocks dopamine receptors involved in the vomiting pathway that traditional antiemetics do not adequately address.
The numbers in context
Single patient case. The abstract does not specify the haloperidol dose used.
How the study worked
Single case report documenting the clinical presentation, failed conventional treatments, and successful response to haloperidol in a patient with cannabinoid hyperemesis syndrome.
What this study cannot tell us
Single case report provides the lowest level of clinical evidence. No control comparison or dosing protocol was established. The mechanism of action for haloperidol in CHS is not fully understood.
How to read the evidence
Single case report, providing the lowest tier of clinical evidence. Preliminary but adds to accumulating reports of haloperidol efficacy in CHS.
When this study was published
Published in 2017.
The bigger picture
CHS represents one of the clearest adverse effects of chronic cannabis use. The emergence of haloperidol as a treatment option is notable because standard antiemetics often fail in CHS, and hot showers, while providing temporary relief, are not a practical long-term solution for acute episodes.
Questions still open
- Does haloperidol work for CHS through dopamine blockade, 5-HT2A antagonism, or another mechanism? Would a clinical trial confirm its effectiveness across a larger patient population? Is there an optimal dosing protocol for haloperidol in CHS?
Common questions
What is cannabinoid hyperemesis syndrome?
How is CHS treated acutely?
Read the original research
Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
BMJ case reports, 2017
Citation
Inayat, Faisal; Virk, Hafeez Ul Hassan; Ullah, Waqas; Hussain, Qulsoom. (2017). Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?. BMJ case reports, 2017. https://doi.org/10.1136/bcr-2016-218239
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk